As per MRFR analysis, the China Geographic Atrophy GA Market Size was estimated at 1.62 (USD Billion) in 2024.The China Geographic Atrophy GA Market Industry is expected to grow from 1.67(USD Billion) in 2025 to 3.62 (USD Billion) by 2035. The China Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 7.286% during the forecast period (2025 - 2035).
The China Geographic Atrophy (GA) market is currently seeing several key market drivers that are shaping its landscape. A significant factor is the increasing prevalence of age-related macular degeneration (AMD), which is anticipated to rise as the population ages. As the elderly demographic in China grows, the need for effective treatments and early intervention in GA becomes more critical. Additionally, advancements in technology and research are propelling innovations in treatment options, with a focus on developing therapies that are less invasive and more effective. There are notable opportunities to be explored within this market as well.
The Chinese government's commitment to improving healthcare and increasing funding for eye care services creates an encouraging environment for new products and treatments. Enhanced collaboration between pharmaceutical companies and research institutions is paving the way for breakthroughs in understanding GA and its management.
Furthermore, public awareness campaigns regarding eye health are expected to create a larger patient base seeking treatments, thus driving market growth. In recent times, there a clear trend towards personalized medicine and the use of gene therapy in treating GA. Research institutions in China are increasingly focusing on tailored therapies that take into account the genetic factors contributing to the condition.
Digital health solutions, such as telemedicine and mobile health apps for monitoring eye health, are also emerging as essential tools for patient management. This shift towards more integrated and patient-centered care models is transforming how GA is treated in China, indicating a rapidly evolving market that is adapting to the needs of its population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Increasing Aging Population
China is experiencing a significant demographic shift as its population ages. According to the National Bureau of Statistics of China, individuals aged 60 and older are projected to reach over 400 million by 2040, constituting roughly 28% of the total population. This rising older demographic is particularly susceptible to age-related macular degeneration, including Geographic Atrophy (GA), which is expected to drive the demand in the China Geographic Atrophy GA Market Industry.An example, Chinese Ophthalmology Society, is actively working on this issue by advancing awareness and training for eye care specialists, which further develops the market.
Advances in Medical Technology
The rapid advancement of medical technologies, including imaging techniques and treatment methodologies, is pivotal for the China Geographic Atrophy GA Market Industry. Technologies such as Optical Coherence Tomography (OCT) are becoming widely available, allowing for better diagnosis and monitoring of GA. The Chinese government has also initiated policies to support Research and Development (R&D) in ocular therapeutics, with funding increasing by 20% annually over the past decade.
This boost in technology is critical, as it not only enhances patient outcomes but also increases the prevalence of diagnosed cases of GA, driving market growth.
Growing Healthcare Expenditure
Healthcare expenditure in China is on the rise, with the National Health Commission reporting an increase in health spending from 6% of GDP in 2010 to approximately 7.3% in 2022. This trend is expected to continue as the government emphasizes improving healthcare access and quality. With increased healthcare spending, more resources can be allocated toward the diagnosis and treatment of conditions like Geographic Atrophy.
The Chinese Ministry of Health aims to expand health insurance coverage for eye-related conditions, which will result in a larger patient base being able to seek treatment, thus bolstering the China Geographic Atrophy GA Market Industry.
The Age Group segment within the China Geographic Atrophy GA Market significantly influences the overall dynamics and growth trends in this health sector. The increasing prevalence of geographic atrophy, particularly among older populations, underscores the importance of focusing on individuals above 60 years of age. This demographic is particularly vulnerable due to the natural aging process, which can lead to degenerative eye diseases like geographic atrophy.
Individuals above the age of 75 represent a critical sub-segment, as they often experience compounded health issues that increase their susceptibility to vision loss. Growth in this segment is driven by several factors, including an aging population, improved access to healthcare services, and increasing awareness about eye health.
Market data shows that significant strides in research and development are being made to address the needs of these aging individuals, particularly as they represent a substantial portion of the patient population requiring treatment options for geographic atrophy. The Chinese government has also prioritized healthcare improvements for the elderly, thus creating a conducive environment for innovative treatment solutions tailored to the unique needs of older patients.
Furthermore, demographic shifts indicate a rising number of individuals reaching these age thresholds, indicating the potential for growth in the market as more people are living longer. The China Geographic Atrophy GA Market segmentation, particularly focusing on these age brackets, not only highlights the challenges faced by older adults but also presents an opportunity for healthcare providers and pharmaceutical companies to develop targeted therapies.
It is essential for stakeholders in the industry to recognize the importance of these age segments, as they are likely to dominate future care paradigms due to their specific healthcare needs. Collaborative efforts among healthcare service providers, policy-makers, and researchers will be crucial in addressing the therapies and intervention strategies needed for these age groups. As the demand for effective treatments grows, the industry must adapt to meet the unique requirements of these aging populations, ensuring that healthcare solutions are both accessible and applicable to those affected by geographic atrophy in China.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Diagnosis segment of the China Geographic Atrophy GA Market plays a crucial role in the assessment and management of geographic atrophy, a progressive retinal disease. Diagnostics tools like Fundus Autofluorescence are essential for visualizing retinal structures, allowing for early detection of atrophic changes. In China, the increasing prevalence of age-related macular degeneration is driving the demand for advanced diagnostic imaging technologies.
Optical Coherence Tomography Angiography is often utilized for its ability to provide detailed cross-sectional images of retinal blood vessels, assisting healthcare professionals in understanding the disease's progression more effectively.Meanwhile, Multifocal Electroretinography is significant as it evaluates the functional status of the retina, making it imperative for personalized treatment plans.
This segment's growth is further supported by rising healthcare investments and advancements in imaging technologies, which present both challenges and opportunities for market players in addressing the specific needs of patients in China. The emphasis on early diagnosis coupled with research into innovative diagnostic methods indicates a positive trajectory for this segment, aligning with China's broader goals in enhancing healthcare quality.
The Therapeutic Agents Clinical Phase segment within the China Geographic Atrophy GA Market presents a dynamic landscape of innovation and research with a robust structure supporting drug development. This segment comprises various stages including Late-Stage, Phase II, Phase I, Pre-Clinical Stage, and Discovery Candidates, each playing a critical role in the journey toward efficient treatments. Late-Stage developments are crucial as they often determine the commercial viability and efficacy of therapies moving forward.
Phase II trials are significant for assessing the effectiveness of treatments and optimizing dosages, while Phase I focuses on safety and tolerability, laying the groundwork for subsequent research.The Pre-Clinical Stage is essential for validating new drug candidates before they reach human trials, making it a cornerstone of the drug development process. Discovery Candidates represent the innovative edge of the market, showcasing potential breakthroughs that could reshape treatment options.
Together, these segments leverage China's expansive healthcare infrastructure and increasing investments in Research and Development, aiming to address the unmet needs of patients suffering from geographic atrophy. With growing collaboration among academia, industry, and governmental support, the Therapeutic Agents Clinical Phase segment is positioned to drive significant advancements in the treatment landscape.
China Geographic Atrophy GA Market Key Players and Competitive Insights:
In recent years, the China Geographic Atrophy GA Market has garnered significant attention due to the increasing prevalence of age-related macular degeneration, particularly the dry form that leads to geographic atrophy. This segment of the ophthalmic market is characterized by a rapidly growing patient population, heightened awareness among healthcare providers, and advances in treatment options. A diverse range of pharmaceutical companies, biotech firms, and research institutions are penetrating this landscape, vying for competitive advantage through research and development, strategic partnerships, and innovative therapeutic solutions.
The dynamics of this market are influenced by regulatory policies, reimbursement frameworks, and the demand for effective intervention therapies aimed at slowing disease progression.Roche has established a noteworthy presence in the China Geographic Atrophy GA Market through its commitment to developing innovative solutions tailored to address the unmet needs of patients. The company's strong research and development pipeline, combined with its robust marketing capabilities, positions it favorably in this competitive landscape. Roche's strengths lie in its extensive experience in the pharmaceutical industry, well-equipped distribution channels, and collaborative initiatives with local healthcare providers and institutions.
These strategic alliances not only facilitate a better understanding of the regional market dynamics but also enable Roche to adapt its offerings to suit local treatment protocols and patient preferences, thereby enhancing its market share in this critical area of ophthalmology.Eyenovia is carving out its niche in the China Geographic Atrophy GA Market with an emphasis on novel delivery technologies and therapeutic products designed for ocular conditions. The company's key offerings, including its proprietary formulations, are designed to improve patient adherence and outcomes. Eyenovia's market presence is bolstered by collaborations with local research entities and strategic partnerships that allow it to effectively navigate the regulatory landscape unique to China.
With ongoing investments in clinical trials and research initiatives aimed at understanding the specific needs of the Chinese population suffering from geographic atrophy, Eyenovia is enhancing its competitive position. Furthermore, the company's focus on innovation and adaptability in the face of evolving market demands reflects its strengths, making it a noteworthy player in the market. Eyenovia's strategic movements within mergers and acquisitions further enable it to expand its resource base and accelerate development timelines, positioning it for growth in the burgeoning Chinese ophthalmic sector.
Key Companies in the China Geographic Atrophy GA Market Include:
China Geographic Atrophy GA Market Industry Developments
Recent developments in the China Geographic Atrophy (GA) Market indicate a growing focus on innovative treatments and collaborations among leading companies. Roche has recently accelerated its Research and Development efforts in gene therapies targeting age-related macular degeneration, which is a significant driver for GA treatment advancements. Eyenovia has been making strides with its Optejet delivery system, essential for targeted therapies, enhancing patient compliance and outcomes. Notably, in September 2023, Regeneron Pharmaceuticals announced a collaboration with Bayer to advance a new GA treatment, ensuring robust clinical trials in the Chinese demographic.
This partnership is expected to leverage both companies' strengths in ophthalmology. Kiora Pharmaceuticals has been scaling its operations in China, fueled by increased market demand for GA treatments. In terms of market growth, the valuation of companies like Novartis and Genentech continues to rise, reflecting the increasing prevalence of GA within the aging population in China, where health authorities have flagged GA as a pressing issue in vision loss. Major happenings in recent years point to a swift evolution of treatment options, particularly around 2022-2023, emphasizing China’s growing role in the global GA Market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.62(USD Billion) |
| MARKET SIZE 2024 | 1.67(USD Billion) |
| MARKET SIZE 2035 | 3.62(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.286% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Roche, Eyenovia, Kiora Pharmaceuticals, Zymeworks, Regeneron Pharmaceuticals, Genentech, Adverum Biotechnologies, Novartis, Vascular Biogenics, Achieve Life Sciences, Bayer, Oxurion, Alder BioPharmaceuticals, Santen Pharmaceutical, Aldeyra Therapeutics |
| SEGMENTS COVERED | Age Group, Diagnosis, Therapeutic Agents Clinical Phase |
| KEY MARKET OPPORTUNITIES | Aging population driving demand, Increasing awareness and diagnosis, Growing investment in R&D, Emerging novel therapies, Expanding healthcare infrastructure |
| KEY MARKET DYNAMICS | aging population, increasing prevalence, innovative treatment options, government healthcare initiatives, rising awareness and diagnosis |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The market is expected to be valued at 1.67 USD Billion in 2024.
By 2035, the market is projected to reach a value of 3.62 USD Billion.
The expected CAGR for the market during this period is 7.286%.
The age group above 60 years holds the largest market share, valued at 1.0 USD Billion in 2024.
The market size for the age group above 75 years is projected to reach 1.47 USD Billion by 2035.
Major players include Roche, Regeneron Pharmaceuticals, Novartis, and Bayer, among others.
In 2024, the market for the above 60 years group is 1.0 USD Billion, while the above 75 years group is 0.67 USD Billion.
Emerging trends include increased investment in research and development for advanced treatment options.
Challenges may include regulatory hurdles and the need for innovations in existing treatments.
The market is anticipated to show significant growth across all age segments, particularly among those above 60 years.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
